RA Capital Management’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.77B | Hold |
|
|||||
|
2025
Q1 | $1.6B | Buy |
|
|||||
|
2024
Q4 | $1.39B | Buy |
|
|||||
|
2024
Q3 | $1.45B | Sell |
|
|||||
|
2024
Q2 | $1.38B | Hold |
|
|||||
|
2024
Q1 | $1.53B | Buy |
|
|||||
|
2023
Q4 | $1.27B | Sell |
|
|||||
|
2023
Q3 | $1B | Sell |
|
|||||
|
2023
Q2 | $1B | Buy |
|
|||||
|
2023
Q1 | $746M | Hold |
|
|||||
|
2022
Q4 | $850M | Sell |
|
|||||
|
2022
Q3 | $781M | Hold |
|
|||||
|
2022
Q2 | $704M | Hold |
|
|||||
|
2022
Q1 | $888M | Hold |
|
|||||
|
2021
Q4 | $1.02B | Buy |
|
|||||
|
2021
Q3 | $1.18B | Buy |
|
|||||
|
2021
Q2 | $895M | Buy |
|
|||||
|
2021
Q1 | $826M | Buy |
|
|||||
|
2020
Q4 | $978M | Sell |
|
|||||
|
2020
Q3 | $912M | Buy |
|
|||||
|
2020
Q2 | $727M | Hold |
|
|||||
|
2020
Q1 | $553M | Buy |
|
|||||
|
2019
Q4 | $582M | Buy |
|
|||||
|
2019
Q3 | $398M | Hold |
|
|||||
|
2019
Q2 | $476M | Hold |
|
|||||
|
2019
Q1 | $486M | Sell |
|
|||||
|
2018
Q4 | $266M | Hold |
|
|||||
|
2018
Q3 | $300M | Hold |
|
|||||
|
2018
Q2 | $282M | Hold |
|
|||||
|
2018
Q1 | $277M | Sell |
|
|||||
|
2017
Q4 | $224M | Hold |
|
|||||
|
2017
Q3 | $202M | Hold |
|
|||||
|
2017
Q2 | $155M | Buy |
|
|||||
|
2017
Q1 | $151M | Hold |
|
|||||
|
2016
Q4 | $109M | Buy |
|
|||||
|
2016
Q3 | $74M | Buy |
|
|||||
|
2016
Q2 | $45.3M | Buy |
|
|||||
|
2016
Q1 | $40.1M | Buy |
|
|||||
|
2015
Q4 | $30.6M | Buy |
|
|||||
|
2015
Q3 | $25.9M | Sell |
|
|||||
|
2015
Q2 | $33.8M | Buy |
|
|||||
|
2015
Q1 | $17.8M | Buy |
|